If you think advancements in gene technology are only for rare diseases or are relegated to the future, think again. The first two Covid vaccines to receive approvals are using mRNA technology, which is a new breed of vaccines. This technology enabled scientists to generate a vaccine candidate within 48 hours of having the Covid genetic sequence.
We expect that gene therapy and other genetic technologies will drive seismic shifts across the entire healthcare landscape over the next decade, bringing us to a period of Biotech 2.0, where drugs are far more efficacious and convenient.
Amanda Birdsey-Benson, senior research analyst, Mellon.
Please note the content on this website is for Investment Professionals only and should be shared responsibly. No other persons should rely on the information contained within this website.
Investment Managers are appointed by BNY Mellon Investment Management EMEA Limited (BNYMIM EMEA), BNY Mellon Fund Managers Limited (BNYMFM), BNY Mellon Fund Management (Luxembourg) S.A. (BNY MFML) or affiliated fund operating companies to undertake portfolio management activities in relation to contracts for products and services entered into by clients with BNYMIM EMEA, BNY MFML or the BNY Mellon funds.
Thank you for submitting the MarketEye Subscription Form. If you wish to review your Preferences please click here.
